Academic Journal
Q1Clinical Cancer Research
About Clinical Cancer Research
Clinical Cancer Research is a scholarly journal published by American Association for Cancer Research Inc.. SCImago 2025 places it in Q1 with an SJR of 4.751 and an H-index of 405.
Its listed coverage is 1995-2026 and its research categories include Cancer Research (Q1); Oncology (Q1). The 2025 dataset reports 519 documents and 16520 citations across the latest three-year reporting window.
About Clinical Cancer Research: Advancing Hope Through Innovation
Clinical cancer research plays a critical role in the ongoing fight against cancer. It involves the study of cancer treatment and prevention through carefully designed clinical trials, aiming to improve patient outcomes, discover more effective therapies, and deepen our understanding of cancer biology. As cancer remains one of the leading causes of death worldwide, clinical research stands as a beacon of hope, offering new possibilities for early detection, targeted treatments, and potential cures.
What Is Clinical Cancer Research?
Clinical cancer research refers to the scientific studies conducted on human participants to evaluate the effectiveness, safety, and side effects of new cancer treatments. These can include drugs, medical devices, biological therapies, or surgical techniques. The ultimate goal is to find better ways to treat cancer, enhance quality of life, and extend survival rates.
Research typically progresses through several phases:
-
Phase I focuses on determining a safe dosage and identifying side effects.
-
Phase II assesses the treatment’s effectiveness.
-
Phase III compares the new treatment with the current standard of care.
-
Phase IV takes place after FDA approval to monitor long-term effects.
Importance of Clinical Cancer Research
Clinical cancer research is vital because it translates laboratory discoveries into life-saving treatments. Through clinical trials, researchers can test breakthrough therapies, such as immunotherapy, precision medicine, and gene editing, that have the potential to revolutionize cancer care.
Additionally, clinical research enables:
-
Improved survival rates by offering patients access to cutting-edge treatments before they’re widely available.
-
Personalized medicine by tailoring therapies to individual genetic profiles.
-
Better understanding of cancer progression, resistance, and recurrence.
Recent Advancements in Cancer Research
Thanks to continuous clinical research, there have been significant advancements in cancer treatment over the past decade. Immunotherapies, like checkpoint inhibitors and CAR T-cell therapy, have shown remarkable success in treating cancers previously considered untreatable. Targeted therapies, designed to attack specific cancer cells while sparing healthy ones, are changing the landscape of cancer care.
Moreover, liquid biopsies and biomarker testing are improving early detection and monitoring of cancer, leading to more proactive and precise interventions.
How to Participate in Clinical Trials
Patients interested in joining a clinical trial should consult with their oncologist to understand their options. Participation is voluntary and involves a detailed informed consent process. Clinical trials are conducted under strict ethical and safety guidelines to protect participants.
Websites like ClinicalTrials.gov offer searchable databases for ongoing studies across the globe.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope of Clinical Cancer Research: Advancing the Future of Oncology
Clinical cancer research plays a pivotal role in the ongoing fight against cancer. This dynamic field focuses on translating basic scientific discoveries into practical therapies, improving diagnostics, and enhancing patient care. As cancer remains one of the leading causes of death worldwide, the scope of clinical cancer research continues to expand, driven by technological advancements, personalized medicine, and a deeper understanding of cancer biology.
What Is Clinical Cancer Research?
Clinical cancer research involves studies conducted with cancer patients or healthy volunteers aimed at evaluating new treatments, improving current therapies, and uncovering the mechanisms behind cancer development. These studies range from early-phase clinical trials testing the safety of novel drugs to large-scale randomized controlled trials assessing treatment efficacy.
The ultimate goal is to develop safe, effective, and targeted therapies that improve survival rates and quality of life for cancer patients. Clinical cancer research bridges the gap between laboratory findings and real-world treatment, ensuring that scientific innovations are translated into meaningful clinical outcomes.
Key Areas Within Clinical Cancer Research
-
Early Detection and Diagnosis
Research into improved screening tools and diagnostic imaging is crucial. Early detection of cancer significantly increases the chances of successful treatment. Clinical studies evaluate new biomarkers, genetic tests, and imaging technologies that help diagnose cancers at an earlier, more treatable stage. -
Targeted Therapies and Immunotherapy
One of the most exciting areas in cancer research is the development of targeted therapies and immunotherapies. These treatments aim to attack cancer cells while minimizing harm to healthy tissues. Clinical trials are essential in testing the safety and efficacy of these cutting-edge approaches. -
Personalized Medicine
Precision oncology uses genetic and molecular profiling to tailor treatments to individual patients. Clinical research enables oncologists to identify which therapies are most likely to benefit specific subgroups of patients, reducing trial-and-error treatment and improving outcomes. -
Survivorship and Quality of Life
As survival rates improve, research also focuses on the long-term effects of cancer treatment. Clinical studies explore ways to reduce side effects, manage symptoms, and support the mental and emotional well-being of survivors. -
Prevention and Risk Reduction
Clinical research isn’t only about treating cancer—it also plays a key role in prevention. Studies assess the effectiveness of vaccines, lifestyle interventions, and medications in reducing cancer risk among high-risk populations.
The Importance of Clinical Trials
Clinical trials are at the heart of clinical cancer research. They are the gold standard for evaluating new treatments and improving current protocols. Participation in clinical trials allows patients to access promising new therapies before they become widely available.
Recent Research Articles
Latest publications matched automatically by ISSN.
Phase 1 trial and biomarker analysis of Buparlisib with weekly Cisplatin and Radiotherapy in high risk locally advanced squamous cell cancer of the Head and Neck.
Jochen H. Lorch, Kristine Wong, Roy B. Tishler, Robert I. Haddad et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-21-3677Glypican-3-Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models
Woonghee Lee, Joon-Yong Chung, Stephen Adler, Falguni Basuli et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-1613A phase II trial of chemotherapy-free neoadjuvant camrelizumab plus apatinib for resectable HNSCC: pathological response and vascular-immune crosstalk
Yaqiong Jie, Zhuo Chen, Lihuang Chen, Yushuo Zhang et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-0466Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial
Gary Middleton, Richard Buchanan, Joshua Savage, Joe De La Mata Chicharro et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-1365ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer
Nicholas Mai, Sharanya Nag, Bo Liu, Wanyi Chen et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-0198Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial
Jin Zhang, Jinhai Zhu, Yaping Yang, Dong Song et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-1604Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
Niklas Klümper, Thomas Büttner, Sebastian Rauch, Stefanie Zschäbitz et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-0093Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin-6: Analysis of the Phase 1/1b Trial
Junjie Hu, Xingyi Zhong, Yuxiang Ma, Jing Luo et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-26-1896Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study
Mustafa Özgüroğlu, Myung-Ju Ahn, Xiaorong Dong, James Chih-Hsin Yang et al.
2026-09-09 · DOI: 10.1158/1078-0432.ccr-25-4523Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
S. Daniel Haldar, Meredith Wetzel, Jiayun Lu, Jae W. Lee et al.
2026-09-02 · DOI: 10.1158/1078-0432.ccr-25-2699Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Kiwan Kim, Seong-Won Song, Yeongha Jeon, Soyoung Choi et al.
2026-09-02 · DOI: 10.1158/1078-0432.ccr-26-0645DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors
Céline Chauvin, Ryszard Wimmer, Ludovica Brunetti, Joanna Cyrta et al.
2026-09-02 · DOI: 10.1158/1078-0432.ccr-25-3915Expression of Concern: Pancreatic Tumor Suppression by Benzyl Isothiocyanate Is Associated with Inhibition of PI3K/AKT/FOXO Pathway
Srinivas Reddy Boreddy, Kartick C. Pramanik, Sanjay K. Srivastava
2026-09-01 · DOI: 10.1158/1078-0432.ccr-26-2724Targetable S100–RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer
Wenjuan Dong, Shiruo Wang, Bill Chan, Matthew Vasquez et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-25-4894FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma
William F. Maguire, Elaine Chang, Flora Mulkey, Vicky Hsu et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-26-1154Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases
Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-26-1610Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Kenichi Harano, Takehiro Nakao, Shin Nishio, Takahiro Katsuda et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-25-4887Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Aman Chauhan, Heidi L. Weiss, Charles Kunos, Rani Jayswal et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-26-0686Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study
Jennifer Y. Sheng, Marianna L. Zahurak, Faith Too, Amanda Montanari et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-26-0270Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
Xing Zhang, Bushu Xu, Qiuzhong Pan, Ruiqing Peng et al.
2026-08-28 · DOI: 10.1158/1078-0432.ccr-26-0658Reviews
Community Reviews
Version History
April 21, 2025 at 10:04 am
April 21, 2025